单剂Ad26.COV2.S引发持久抗体应答且加强后大幅提升:两项随机临床试验
两项随机、双盲、安慰剂对照的1/2a期和2期试验评估单剂Ad26.COV2.S(5×10^10病毒颗粒)后抗体持久性及加强效果。单剂后中和抗体稳定至少8-9个月,结合抗体稳定至少6个月,不受年龄影响。2个月加强使结合抗体提升4.9-6.2倍,6个月加强7天后提升9倍,Beta变异株中和抗体28天提升5.0倍,四分之一剂量加强也有效。
要点
- 单剂Ad26.COV2.S后中和抗体稳定至少8-9个月,结合抗体稳定至少6个月。
- 2个月加强(5×10^10 vp)后14天结合抗体较初免后28天提升4.9-6.2倍。
- 6个月加强后7天结合抗体提升9倍,Beta株中和抗体28天提升5.0倍。
核心结论
- 单剂Ad26.COV2.S引发至少8个月的持久抗体应答并产生免疫记忆。
- 加强诱导的结合和中和抗体应答快速且强劲,四分之一剂量也有效,且间隔更长时更强。
研究设计与样本
- 随机、双盲、安慰剂对照的1/2a期和2期试验。
- 1/2a期参与者于2020年7月22日至12月18日入组:队列1a(18-55岁,N=25)、队列2a(18-55岁,N=17)、队列3(≥65岁,N=22);2期参与者于2020年9月14日至22日入组(18-55岁和≥65岁,N=73)。
- 参与者接受单剂Ad26.COV2.S(5×10^10 vp),随后接受5×10^10 vp或1.25×10^10 vp加强剂量。
- 采用病毒中和试验(VNA)在首剂后约8-9个月测定中和抗体水平;采用酶联免疫吸附试验和假病毒VNA在首剂后6个月及加强后7天和28天评估结合和中和抗体水平。
主要发现
- 单剂Ad26.COV2.S引发稳定中和抗体至少8-9个月,稳定结合抗体至少6个月,不受年龄影响。
- 5×10^10 vp的2个月加强剂量在加强后14天使结合抗体较初免后28天提升4.9-6.2倍。
- 6个月加强在加强后7天使结合抗体水平提升9倍。
- 加强后28天观察到针对Beta变异株的中和抗体提升5.0倍。
- 1.25×10^10 vp的6个月加强在加强后7天使结合抗体水平较加强前提升3.6倍,两个年龄组加强后应答幅度相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ad26.COV2.S is a well-tolerated and effective vaccine against COVID-19. We evaluated durability of anti-SARS-CoV-2 antibodies elicited by single-dose Ad26.COV2.S and the impact of boosting. METHODS: In randomized, double-blind, placebo-controlled, phase 1/2a and phase 2 trials, participants received single-dose Ad26.COV2.S (5 × 1010 viral particles [vp]) followed by booster doses of 5 × 1010 vp or 1.25 × 1010 vp. Neutralizing antibody levels were determined by a virus neutralization assay (VNA) approximately 8-9 months after dose 1. Binding and neutralizing antibody levels were evaluated by an enzyme-linked immunosorbent assay and pseudotyped VNA 6 months after dose 1 and 7 and 28 days after boosting. RESULTS: Data were analyzed from phase 1/2a participants enrolled from 22 July-18 December 2020 (Cohort 1a, 18-55 years [y], N = 25; Cohort 2a, 18-55y, N = 17; Cohort 3, ≥65y, N = 22), and phase 2 participants from 14 to 22 September 2020 (18-55y and ≥ 65y, N = 73). Single-dose Ad26.COV2.S elicited stable neutralizing antibodies for at least 8-9 months and stable binding antibodies for at least 6 months, irrespective of age. A 5 × 1010 vp 2-month booster dose increased binding antibodies by 4.9- to 6.2-fold 14 days post-boost versus 28 days after initial immunization. A 6-month booster elicited a steep and robust 9-fold increase in binding antibody levels 7 days post-boost. A 5.0-fold increase in neutralizing antibodies was observed by 28 days post-boost for the Beta variant. A 1.25 × 1010 vp 6-month booster elicited a 3.6-fold increase in binding antibody levels at 7 days post-boost versus pre-boost, with a similar magnitude of post-boost responses in both age groups. CONCLUSIONS: Single-dose Ad26.COV2.S elicited durable antibody responses for at least 8 months and elicited immune memory. Booster-elicited binding and neutralizing antibody responses were rapid and robust, even with a quarter vaccine dose, and stronger with a longer interval since primary vaccination. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04436276, NCT04535453.
引用
- Sadoff J, Le Gars M, Brandenburg B, et al. Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials. Vaccine. 2022. PMID: 35667914. doi:10.1016/j.vaccine.2022.05.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。